XL765 is an orally available small molecule that has been shown in preclinical studies to selectively inhibit the activity of phosphoinositide-3 kinase (PI3K) and mammalian target of rapamycin (mTOR). It... It is being developed by Exelixis, Inc.
- Mechanism
- Curator reviewed
XL765 inhibits the activity of phosphoinositide-3 kinase (PI3K), which is frequently activated in tumors and promotes cell growth, survival and resistance to chemotherapy and radiotherapy. XL765 also inhibits mammalian target of rapamycin (mTOR), which also is activated frequently in human tumors and plays a central role in tumor cell growth. XL765 potently inhibits Class I PI3K isoforms and mTOR.
- Primary indication
- For the treatment of various forms of cancer.Curator reviewed
- Code names
- XL765
Resolves to
What you can answer from here — as of April 02, 2025
Which drugs share a target with XL765, and which of those have an active Phase 3 trial?
Create a free account or log in to explore the full data card.
Create Account